» Articles » PMID: 22385985

Chronic HCV Infection is a Risk of Atherosclerosis. Role of HCV and HCV-related Steatosis

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2012 Mar 6
PMID 22385985
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: HCV and NAFLD are associated with atherosclerosis in general population. The prevalence of atherosclerosis in chronic hepatitis C (CHC) patients is unknown. We hypothesized that HCV per se and HCV-related steatosis could favour atherosclerosis. Thus, in CHC patients we assessed: (a) the prevalence of atherosclerosis; (b) the role of HCV, cardio-metabolic risk factors and hepatic histology.

Methods: Overall, 803 subjects were enrolled: (A) 326 patients with liver biopsy-proven treatment naive CHC (175 with and 151 without steatosis); (B) 477 age and gender matched controls, including 292 healthy subjects without steatosis (B1) and 185 with NAFLD (B2). Carotid atherosclerosis (CA), assessed by high-resolution B-mode ultrasonography, was categorized as either intima-media thickness (IMT: >1mm) or plaques (≥ 1.5mm).

Results: CHC patients had a higher prevalence of CA than controls (53.7% vs 34.3%; p<0.0001). Younger CHC (<50 years) had a higher prevalence of CA than controls (34.0% vs 16.0%; p<0.04). CHC patients without steatosis had a higher prevalence of CA than B1 controls (26.0% vs 14.8%; p<0.02). CHC with steatosis had a higher prevalence of CA than NAFLD patients (77.7% vs 57.8%, p<0.0001). Viral load was associated with serum CRP and fibrinogen levels; steatosis with metabolic syndrome, HOMA-IR, hyperhomocysteinemia and liver fibrosis. Viral load and steatosis were independently associated with CA. Diabetes and metabolic syndrome were associated with plaques.

Conclusion: HCV infection is a risk factor for earlier and facilitated occurrence of CA via viral load and steatosis which modulate atherogenic factors such as inflammation and dysmetabolic milieu.

Citing Articles

Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.

Liu C, Seto W, Yu M Hepatol Int. 2024; 18(Suppl 2):897-908.

PMID: 39115632 DOI: 10.1007/s12072-024-10699-x.


The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD.

Yang Z, Yang J, Cai J, Zhang X, Zhang P, She Z Rev Cardiovasc Med. 2024; 24(6):157.

PMID: 39077530 PMC: 11264127. DOI: 10.31083/j.rcm2406157.


Understanding the relationship between HCV infection and progression of kidney disease.

Zhang M, Han Z, Lin Y, Jin Z, Zhou S, Wang S Front Microbiol. 2024; 15:1418301.

PMID: 39006752 PMC: 11239345. DOI: 10.3389/fmicb.2024.1418301.


.

Laabidi S, Medhioub M, Khsiba A, Bach Ali A, Mohamed A, Hamzaoui L Tunis Med. 2024; 102(3):170-175.

PMID: 38545713 PMC: 11358770. DOI: 10.62438/tunismed.v102i3.4601.


Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.

Fernandez C, Alkhalifah M, Afsar H, Pappachan J Pathogens. 2024; 13(1).

PMID: 38251375 PMC: 10821334. DOI: 10.3390/pathogens13010068.